Introduction {#sec1}
============

Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) is characterized by impaired function and differentiation of T, B, and natural killer (NK) cells.[@bib1], [@bib2] Non-immunological abnormalities may also occur, including failure to thrive, hepatic disorders, renal disease, skeletal alterations, and neurological/cognitive/behavioral deficits.[@bib1], [@bib3], [@bib4], [@bib5] ADA-SCID is rare: reported incidence rates range from 0.22 to 0.68 per 100,000 live births,[@bib6], [@bib7], [@bib8], [@bib9] corresponding to fewer than 50 children per year in the United States and European Union combined.

From birth onward, patients with ADA-SCID are at risk of death due to life-threatening opportunistic infections; the disorder is fatal if untreated. Enzyme replacement therapy (ERT) in the form of polyethylene glycol-modified bovine adenosine deaminase (PEG-ADA) is beneficial for some patients with ADA-SCID and has been administered to over 150 patients.[@bib10], [@bib11] However, immune reconstitution is variable and usually does not persist long term; approximately 10% of treated children develop neutralizing antibodies to PEG-ADA and require an increase in dosage, administration of corticosteroids, or cessation of therapy.[@bib12], [@bib13], [@bib14] For patients who received PEG-ADA between 1986 and 2008, the overall probability of 20-year survival on PEG-ADA was estimated to be 78%.[@bib1] A study of PEG-ADA treatment in 42 patients with ADA-SCID reported four deaths from infections.[@bib10]

Patients with ADA-SCID may be effectively treated with hematopoietic stem cell transplant (HSCT). The best outcomes are achieved when a human leukocyte antigen (HLA)-matched sibling donor is used. However, this type of donor is available for less than 25% of patients with ADA-SCID.[@bib15] In contrast, the survival rate is low (less than 68%) for patients with ADA-SCID who receive HSCTs from HLA-matched unrelated donors.[@bib16] In a multicenter retrospective study of patients with ADA-SCID, the majority (63%) of deaths following all types of transplantations occurred within the first 100 days after HSCT. The reported causes of death were mainly related to pneumonitis/respiratory failure and sepsis, which caused more than 50% of all deaths. Other causes of death included graft versus host disease (GvHD) (15%) and fungal infection (incidence not reported). Only 2 of the 13 deaths that occurred after 100 days were attributed to HSCT-related complications.[@bib16]

Gene therapy (GT) provides an opportunity to treat ADA-SCID while reducing the risk of side effects, such as GvHD and circumventing donor availability limitations. Treatment with an autologous cell fraction containing CD34^+^ cells carrying a human ADA cDNA sequence that has been inserted using a retroviral vector (RV) has previously been shown to result in immune system reconstitution for patients with ADA-SCID.[@bib17], [@bib18], [@bib19], [@bib20], [@bib21] While there are publications focusing on efficacy follow-up of ADA-SCID patients treated with HSCT or ERT, there is a paucity of published safety information. Similarly, high-level safety data for GT-treated ADA-SCID patients have been previously reported.[@bib19] Here are provided uniquely detailed analyses of short- and medium-term safety (up to 13 years) within a GT-treated ADA-SCID patient population, which were part of the dossier presented to European regulatory authorities for marketing authorization. These analyses specifically focus on areas of special interest, including infections, neurologic and hearing impairment, autoimmunity, hepatic findings (not previously reported), and malignancy.

Results {#sec2}
=======

Unless otherwise noted, all results are from a May 2014 data cut as part of the dossier submitted to the European regulatory agency.

Study Population {#sec2.1}
----------------

Eighteen patients with ADA-SCID (11 male) were treated with GT (dose range, 0.9 to 18.2 × 10^6^ CD34^+^ cells/kg; vector copy number range, 0.06 to 2.28 copies/cell).[@bib18], [@bib19] The median age at GT was 1.7 years (range: 0.5 to 6.1 years); 15 patients had a previous history of ERT with PEG-ADA, and four had a previous history of unsuccessful haploidentical HSCT.

Efficacy {#sec2.2}
--------

All 18 patients are alive as of June 2017 (A.A., unpublished data). Median follow-up at data cut (May 2014) was 6.9 years (range, 2.3 to 13.4 years). Engraftment of gene-modified cells led to immune reconstitution, demonstrated by immunoglobulin (IG) production, decreased intravenous (i.v.) IG use, antibody response after vaccination, normalization of T cell subsets (CD3^+^, CD4^+^, and CD8^+^ cells), evidence of thymopoiesis, and sustained T cell proliferative capacity. Three patients resumed long-term PEG-ADA treatment due to poor immune reconstitution after GT. One of these patients received a second GT treatment in the absence of further busulfan conditioning, but this treatment was also unsuccessful. That patient remains on ERT and is enrolled in long-term follow-up (LTFU). The other two patients received HLA-matched HSCTs from siblings (not originally available), followed by successful engraftment of donor stem cells and withdrawal from LTFU.

Adverse Events {#sec2.3}
--------------

A short summary of adverse events has been previously reported;[@bib19] additional details are below. In brief, adverse events (AEs) were mostly grade 1 or grade 2 in severity and were reported by all 18 patients. The incidence rates were greatest for the pre-treatment (start date after screening visit but prior to day −4), treatment (start date on day −4 up to and including start of GT \[day 0\], includes duration of busulfan conditioning), and 3-month follow-up (day 1, after infusion of investigational medicinal product, up to and including day 136) phases compared with the later phases ([Table 1](#tbl1){ref-type="table"}). The most frequently reported AEs were upper respiratory infection, gastroenteritis, diarrhea, and pyrexia. Two investigator-assessed treatment-related AEs were reported in a single patient: grade 1 hepatic steatosis and grade 2 abnormal white blood cell (decreased T cell receptor Vβ repertoire); both developed more than 8 years post-GT and were ongoing. Fifteen patients reported a total of 39 serious AEs (SAEs). Two patients experienced seven SAEs each. The most frequently reported SAEs were device-related infections, gastroenteritis, and pneumonia ([Table 2](#tbl2){ref-type="table"}). No SAEs were fatal or related to the GT medicinal product.Table 1Summary of Adverse Events Reported in Three or More PatientsEvent (Rate per 100 Patient Years \[No. of Patients\])Pre-treatment[a](#tblfn1){ref-type="table-fn"} (n = 17)Treatment (n = 17)3-Month Follow-up (n = 17)3-Year Follow-up (n = 17)7-Year Follow-up (n = 13)≥8-Year Follow-up (n = 6[b](#tblfn2){ref-type="table-fn"})Total (n = 18)Infections and Infestations445 (12)859 (2)844 (14)229 (17)127 (12)50 (5)203 (18)Upper respiratory tract infection19 (1)064 (3)36 (8)17 (5)4 (1)24 (12)Gastroenteritis39 (2)032 (2)22 (8)5 (2)013 (10)Rhinitis39 (2)0016 (8)12 (3)012 (9)Bronchitis0032 (1)16 (5)14 (3)012 (6)Device-related infection0064 (3)12 (4)008 (6)Ear infection19 (1)016 (1)10 (3)9 (2)09 (6)Oral candidiasis58 (3)0111 (4)6 (2)2 (1)011 (6)Nasopharyngitis19 (1)032 (2)10 (4)006 (5)Pneumonia0016 (1)2 (1)5 (2)4 (1)4 (5)Sinusitis39 (2)004 (2)12 (5)07 (5)Urinary tract infection0032 (2)10 (3)5 (1)13 (2)9 (5)*Candida* infection39 (2)016 (1)2 (1)003 (4)Otitis media0016 (1)4 (2)04 (1)3 (4)Pharyngitis0002 (1)5 (2)03 (4[c](#tblfn3){ref-type="table-fn"})*Varicella*0006 (3)2 (1)03 (4)Urinary tract infection (*Escherichia coli*)0016 (1)10 (3)2 (1)05 (3)Skin infection (fungal)0032 (2)004 (1)2 (3)*Hemophilus* infection0006 (3)002 (3)Influenza0002 (1)5 (2)02 (3)Respiratory tract infection19 (1)016 (1)8 (2)005 (3)Sepsis (Staphylococcal)19 (1)016 (1)2 (1)002 (3)Upper respiratory tract infection (bacterial)0032 (2)8 (1)005 (3)Urinary tract infection (Pseudomonal)19 (1)430 (1)48 (3)0004 (3)Investigations407 (12)859 (2)255 (10)53 (13)35 (10)17 (3)66 (17)Antinuclear antibody positive test19 (1)0009 (4)04 (5)Increased blood IgE0006 (3)7 (3)05 (5)Increased hepatic enzyme0080 (4)6 (2)006 (5)Abnormal thorax CT58 (3)002 (1)003 (4)Abnormal tympanometry19 (1)004 (2)2 (1)03 (4)Increased blood alkaline phosphatase19 (1)430 (1)16 (1)2 (1)003 (3)Abnormal protein electrophoresis0016 (1)4 (2)002 (3)Abnormal brain MRI58 (3)000002 (3)Abnormal pulmonary function test0002 (1)5 (2)4 (1)3 (3)Decreased weight0004 (2)2 (1)02 (3)Skin and subcutaneous tissue disorders194 (4)0175 (7)30 (10)21 (5)8 (2)37 (16)Atopic dermatitis19 (1)004 (2)5 (2)04 (5)Skin lesion19 (1)016 (1)4 (2)003 (4)Dermatitis0032 (2)02 (1)02 (3)Rash0016 (1)4 (2)002 (3)Blood and lymphatic system disorders97 (4)0366 (11)26 (8)7 (2)034 (16)Anemia19 (1)048 (3)6 (3)005 (7)Neutropenia00175 (5)4 (2)0010 (6)Eosinophilia19 (1)016 (1)4 (2)003 (4)Respiratory, thoracic, and mediastinal disorders194 (7)032 (2)45 (12)24 (6)17 (3)38 (14)Cough19 (1)0014 (5)12 (3)4 (1)11 (8)Interstitial lung disease39 (2)016 (1)0002 (3)Pneumonitis39 (2)016 (1)0002 (3)Productive cough19 (1)002 (1)2 (1)02 (3)Gastrointestinal disorders97 (4)859 (2)159 (7)24 (7)21 (6)4 (1)30 (13)Diarrhea58 (3)430 (1)64 (4)14 (6)12 (3)016 (10)Vomiting39 (2)430 (1)32 (1)2 (1)2 (1)05 (6)Enteritis0016 (1)4 (1)2 (1)4 (1)4 (3)General disorders and administration site conditions155 (6)1289 (3)16 (1)18 (9)12 (5)020 (12)Pyrexia97 (4)430 (1)16 (1)12 (6)9 (4)013 (8)Nervous system disorders78 (3)0018 (7)12 (3)4 (1)15 (12)Cognitive disorder0006 (3)5 (2)04 (5)Psychomotor hyperactivity19 (1)004 (2)002 (3)Congenital, familial, and genetic disorders194 (8)0022 (6)5 (2)018 (11)Cryptorchism58 (3)006 (3)5 (2)06 (6)Phimosis39 (2)0010 (5)005 (6)Hepatobiliary disorders39 (2)096 (4)12 (3)7 (2)8 (2)15 (10)Hepatic steatosis0032 (1)02 (1)8 (2)4 (4)Hepatomegaly39 (2)002 (1)002 (3)Musculoskeletal and connective tissue disorders78 (4)006 (2)12 (2)09 (7)Foot deformity19 (1)0005 (2)02 (3)Muscle atrophy19 (1)0005 (2)02 (3)Endocrine disorders58 (3)004 (2)2 (1)4 (1)5 (6)Hypothyroidism39 (2)004 (2)003 (4)Vascular disorders39 (2)064 (3)2 (1)2 (1)06 (6)Hypertension19 (1)064 (3)02 (1)05 (5)Neoplasms[d](#tblfn4){ref-type="table-fn"}39 (1)016 (1)6 (1)2 (1)13 (3)8 (5)Skin papilloma00002 (1)13(3)3 (3)[^2][^3][^4][^5][^6]Table 2Serious Adverse Events Following Gene Therapy[a](#tblfn5){ref-type="table-fn"}EventStudy PhaseDuration, DaysOutcomeMaximum Toxicity GradeNeutropenia[b](#tblfn6){ref-type="table-fn"}3-month follow-up29resolvedgrade 4Pneumonia3-month follow-up46resolvedgrade 4Autoimmune thrombocytopenia3-month follow-up12resolvedgrade 3Device-related infection3-month follow-up12resolvedgrade 3Device-related infection3-month follow-up16resolvedgrade 3Epstein-Barr virus infection3-month follow-up9resolvedgrade 3Hypertension3-month follow-up75resolvedgrade 3Pancytopenia3-month follow-up22resolvedgrade 3Sepsis (Staphylococcal)3-year follow-up9resolvedgrade 4Aplastic anemia3-year follow-up120resolvedgrade 3Autoimmune hepatitis3-year follow-up14resolvedgrade 3Autoimmune thrombocytopenia3-year follow-up16resolvedgrade 3Device-related infection3-year follow-up4resolvedgrade 3Device-related infection3-year follow-up14resolvedgrade 3Device-related infection3-year follow-up11resolvedgrade 3Device-related infection3-year follow-up10resolvedgrade 3Device-related infection3-year follow-up17resolvedgrade 3Device-related infection3-year follow-up9resolvedgrade 3Diarrhea3-year follow-up9resolvedgrade 3Fever3-year follow-up4resolvedgrade 3Fibrolipoma[@bib72]3-year follow-up4resolvedgrade 3Gastroenteritis3-year follow-up6resolvedgrade 3Gastroenteritis3-year follow-up7resolvedgrade 3Guillain-Barré syndrome3-year follow-up4resolvedgrade 3Meningitis3-year follow-up17resolvedgrade 3Neutropenia3-month follow-up66resolvedgrade 3Respiratory tract infection3-year follow-up3resolvedgrade 3Upper respiratory tract infection (bacterial)3-year follow-up12resolvedgrade 3Urinary tract infection3-year follow-up10resolvedgrade 3*Varicella*3-year follow-up6resolvedgrade 3Gastroenteritis3-year follow-up28resolvedgrade 2Autoimmune aplastic anemia7-year follow-up10resolvedgrade 3Pneumonia7-year follow-up10resolvedgrade 3Pyoderma7-year follow-up20resolvedgrade 3*Varicella*7-year follow-up8resolvedgrade 3Fever7-year follow-up2resolvedgrade 2Thermal burn7-year follow-up110resolved with sequelaegrade 2Pneumonia≥8-year follow-up8resolvedgrade 3Urinary tract infection≥8-year follow-up4resolvedgrade 2[^7][^8]

Laboratory and Clinical Values {#sec2.4}
------------------------------

Following an initial, transient decrease between baseline and day 14 (consistent with low-dose busulfan treatment), hematology parameters including hemoglobin, hematocrit, and platelet count increased toward pre-treatment values over 3 months to 1 year post-GT.[@bib19] Only white blood cell (WBC) counts increased above pre-treatment values, which is to be expected as lymphocyte counts rise as immune reconstitution progresses post-GT. There was no consistent pattern of concern for clinical chemistry or vital sign values (including heart rate and blood pressure).

Infections {#sec2.5}
----------

Infection AEs were reported for all 18 patients ([Table 1](#tbl1){ref-type="table"}), including those with unsuccessful GT. The three most frequently reported infections were normal, expected childhood infections:[@bib22], [@bib23] upper respiratory tract infection, gastroenteritis, and rhinitis.[@bib19] The incidence rates for the most frequent infections peaked before or during the 3-month follow-up phase and then decreased ([Figure 1](#fig1){ref-type="fig"}). Twenty-four of the 39 SAEs reported post-treatment were infections; all resolved ([Table 2](#tbl2){ref-type="table"}). Six patients reported 10 AEs of central venous catheter (CVC) infections, of which eight were grade 3 SAEs that developed within 3 years of GT; all resolved. Most urinary tract infections (UTIs) occurred during 3-month follow-up and early in 3-year follow-up ([Table 1](#tbl1){ref-type="table"}). Three patients reported three or more UTIs each; two patients had UTI SAEs. Six of the 11 male patients reported UTIs; all six had conditions that predispose for UTIs. UTI events were not related to urinary catheter placement.Figure 1Incidence of Infections in Three or More Patients by Study PhaseIncidence rate calculations include patients who resumed PEG-ADA treatment due to a lack of GT efficacy. In any given phase, only those AEs that were new or worsened after the start of a particular phase were reported.

There were 30 opportunistic infections reported following GT, 18 of them in the 3-month follow-up phase ([Table 3](#tbl3){ref-type="table"}). Most opportunistic infections were grade 1; all resolved. Post-GT, four patients reported *Varicella zoster* virus (VZV) infections, five reported oral candidiasis (three patients had pre-treatment AEs), three reported *Clostridium difficile* infections, and two reported *Aspergillus* infections.Table 3Opportunistic InfectionsEventStudy PhaseDuration, DaysOutcomeMaximum Toxicity Grade*Candida* infectionpre-treatment14resolvedgrade1*Candida* infectionpre-treatmentNRresolvedgrade 1Oral candidiasispre-treatment25resolvedgrade 1Oral candidiasispre-treatment4resolvedgrade 1Oral candidiasispre-treatment51resolvedgrade 1Skin *Candida*pre-treatment13resolvedgrade 1Epstein-Barr virus infection3-month follow-up9resolvedgrade 3 (SAE)*Candida* infection3-month follow-up13resolvedgrade 2*Clostridium difficile* infection3-month follow-up45resolvedgrade 2Epstein-Barr virus infection3-month follow-up26resolvedgrade 2Epstein-Barr virus infection3-month follow-up6resolvedgrade 2Positive *Candida* test3-month follow-up23resolvedgrade 2Pulmonary mycosis3-month follow-up10resolvedgrade 2*Clostridium difficile* colitis3-month follow-up5resolvedgrade 1*Clostridium difficile* colitis3-month follow-up6resolvedgrade 1*Clostridium difficile* infection3-month follow-up217resolvedgrade 1*Cytomegalovirus*3-month follow-up22resolvedgrade 1Oral candidiasis3-month follow-up7resolvedgrade 1Oral candidiasis3-month follow-up13resolvedgrade 1Oral candidiasis3-month follow-up12resolvedgrade 1Oral candidiasis3-month follow-up120resolvedgrade 1Oral candidiasis3-month follow-up6resolvedgrade 1Oral candidiasis3-month follow-upNRresolvedgrade 1Positive *Clostridium* test3-month follow-up15resolvedgrade 1*Varicella*3-year follow-up6resolvedgrade 3 (SAE)Oral candidiasis3-year follow-upNRresolvedgrade 2Oral candidiasis3-year follow-up10resolvedgrade 2*Varicella*3-year follow-up23resolvedgrade 2*Varicella*3-year follow-up19resolvedgrade 2*Aspergillus* infection3-year follow-up16resolvedgrade 1*Candida* infection3-year follow-up335resolvedgrade 1Oral candidiasis3-year follow-up13resolvedgrade 1Positive *Aspergillus* test3-year follow-up7resolvedgrade 1*Varicella*7-year follow-up8resolvedgrade 3 (SAE)Gastroenteritis (cryptosporidial)7-year follow-upNRresolvedgrade 1Oral candidiasis7-year follow-upNRresolvedgrade 1[^9]

Neurologic and Hearing Impairments {#sec2.6}
----------------------------------

All patients had neurological assessments throughout follow-up via specialist exams, instrumental tests, and physical exams. Fourteen patients reported neurologic or hearing AEs at screening.[@bib19] Thirteen patients reported neurologic or hearing AEs post GT. Cognitive disorder and deafness were the most commonly reported events ([Table 4](#tbl4){ref-type="table"}). The majority of events were grade 1 or 2, none were serious, and none were considered by the investigator to be related to treatment. No convulsion AEs were reported.Table 4Neurologic, CNS, and Hearing-Impairment AEsEvent[a](#tblfn7){ref-type="table-fn"}Study PhaseDuration, DaysOutcomeMaximum Toxicity GradeAbnormal brain MRIpre-treatmentNRNRNRAbnormal tympanometrypre-treatmentNRNRNRAlteration in periventricular white matter on brain MRIpre-treatment1,121resolvedNRBroad-based walkingpre-treatmentongoingnot resolvedNREnlarged lateral ventricular on brain MRIpre-treatmentNRNRNRLow-amplitude EEG waves with poor organizationpre-treatmentongoingnot resolvedNRPsychomotor hyperactivitypre-treatment∼2 yearsresolvedNRSensory neural hearing loss (bilateral)pre-treatmentongoingnot resolvedNRHypotoniapre-treatment255resolvedgrade 3Severe mental retardationpre-treatmentongoingnot resolvedgrade 3Cerebral hematomapre-treatment112resolvedgrade 2Deafness (bilateral)pre-treatmentongoingnot resolvedgrade 2Psychomotor retardationpre-treatmentongoingnot resolvedgrade 2Psychomotor retardationpre-treatmentongoingnot resolvedgrade 2Abnormal brain MRIpre-treatment1,122resolvedgrade 1Abnormal brain MRIpre-treatmentongoingnot resolvedgrade 1Abnormal brain scanpre-treatmentongoingnot resolvedgrade 1Abnormal VEPpre-treatment381resolvedgrade 1Arnold-Chiari malformationpre-treatmentongoingnot resolvedgrade 1Attention deficit/hyperactivity disorderpre-treatment1,125resolvedgrade 1Communication disorderpre-treatment1,125resolvedgrade 1Demyelinationpre-treatment1,318resolvedgrade 1Developmental delaypre-treatmentongoingnot resolvedgrade 1Gliosispre-treatmentongoingnot resolvedgrade 1Hypoacusiapre-treatment964resolvedgrade 1Hypothalamo-pituitary disorderpre-treatmentongoingnot resolvedgrade 1Hypothalamo-pituitary disorderpre-treatmentongoingnot resolvedgrade 1Impaired psychomotor skillspre-treatmentongoingnot resolvedgrade 1Mental retardationpre-treatment3003resolvedgrade 1Plagiocephalypre-treatmentNRresolvedgrade 1Psychomotor retardationpre-treatment∼2.5 yearsresolvedgrade 1Sensorineural hypoacusia at BAERpre-treatmentongoingnot resolvedgrade 1Sleep disorderpre-treatment462resolvedgrade 1Tympanic membrane disorderpre-treatmentongoingnot resolvedgrade 1VEP prolonged latencypre-treatment672resolvedgrade 1Gait disturbancetreatment37resolvedgrade 1Middle ear inflammation3-month follow-up5resolvedgrade 1Guillain-Barré syndrome3-year follow-up4resolvedgrade 3Autism3-year follow-upongoingnot resolvedgrade 2Speech disorder3-year follow-upongoingnot resolvedgrade 2Abnormal tympanometry3-year follow-upongoingnot resolvedgrade 1Abnormal tympanometry3-year follow-up1,167resolvedgrade 1Cognitive disorder3-year follow-upongoingnot resolvedgrade 1Cognitive disorder3-year follow-upongoingnot resolvedgrade 1Cognitive disorder3-year follow-upongoingnot resolvedgrade 1Deafness3-year follow-up198resolvedgrade 1Deafness3-year follow-upongoingnot resolvedgrade 1Deafness (bilateral)3-year follow-upongoingnot resolvedgrade 1Deafness (bilateral)3-year follow-up338resolvedgrade 1Developmental delay3-year follow-up2,212resolvedgrade 1Impaired psychomotor skills3-year follow-up∼1.8 yearsresolvedgrade 1Psychomotor hyperactivity3-year follow-up∼1.1 yearsresolvedgrade 1Psychomotor hyperactivity3-year follow-upongoingnot resolvedgrade 1Tympanic membrane disorder3-year follow-upongoingnot resolvedgrade 1Hypoacusia7-year follow-upongoingnot resolvedgrade 2Abnormal tympanometry7-year follow-upongoingnot resolvedgrade 1Cognitive disorder7-year follow-upongoingnot resolvedgrade 1Areflexia7-year follow-up871resolvedgrade 1Cognitive disorder7-year follow-upongoingnot resolvedgrade 1Deafness7-year follow-upongoingnot resolvedgrade 1Disturbance in attention7-year follow-upongoingnot resolvedgrade 1Impaired hearing≥8-year follow-upongoingnot resolvedgrade 3Moderate mental retardation≥8-year follow-upongoingnot resolvedgrade 3Obsessive-compulsive disorder≥8-year follow-upongoingnot resolvedgrade 2[^10][^11]

Autoimmunity {#sec2.7}
------------

Manual record review revealed pre-treatment AEs potentially related to autoimmunity (positive anti-nuclear antibody \[ANA\] test, autoimmune haemolytic anemia, and hypothyroidism) in five patients. Following GT, 12 subjects reported 26 events related to autoimmunity.[@bib19] Grade 1 ANA positivity was the most frequently reported autoimmune event (one event each in five patients) ([Table 5](#tbl5){ref-type="table"}). Seven autoimmunity SAEs were reported and all resolved: anti-neutrophil antibody-induced neutropenia; Guillain-Barré syndrome; two autoimmune thrombocytopenia events in a single patient; and autoimmune aplastic anemia, aplastic anemia, and autoimmune hepatitis in another patient. Other than a single autoimmune aplastic anemia event, all autoimmunity SAEs occurred within the first 3 years post-GT. No systemic allergic events (angioedema, anaphylactic reaction, or severe cutaneous reactions) that could be indicative of immunogenicity to the GT medicinal product were observed.Table 5AEs Potentially Related to AutoimmunityEventStudy PhaseDuration, DaysOutcomeMaximum Toxicity GradeAutoimmune hemolytic anemiapre-treatmentNRresolvedNAChronic autoimmune hemolytic anemiapre-treatmentNAnot resolvedNAHypothyroidismpre-treatmentNAnot resolvedgrade 2Antinuclear antibody positive testpre-treatment3,005resolvedgrade 1Hypothyroidismpre-treatment1,116resolvedgrade 1Hypothyroidismpre-treatmentNAnot resolvedgrade 1Neutropenia3-month follow-up29resolvedgrade 4 (SAE)Autoimmune thrombocytopenia3-month follow-up12resolvedgrade 3 (SAE)Anti-thyroid antibody positive test3-month follow-up648resolvedgrade 1Aplastic anemia[a](#tblfn8){ref-type="table-fn"}3-year follow-up120resolvedgrade 3 (SAE)Autoimmune hepatitis3-year follow-up14resolvedgrade 3 (SAE)Autoimmune thrombocytopenia3-year follow-up16resolvedgrade 3 (SAE)Guillain-Barré syndrome3-year follow-up4resolvedgrade 3 (SAE)Autoimmune thrombocytopenia3-year follow-up46resolvedgrade 3Autoimmune thrombocytopenia3-year follow-upNAnot resolvedgrade 3Autoimmune haemolytic anemia3-year follow-upNRresolvedgrade 2Hypothyroidism3-year follow-upNAnot resolvedgrade 2Hypothyroidism3-year follow-upNAnot resolvedgrade 2Autoimmune hepatitis3-year follow-up211resolvedgrade 1Autoimmune aplastic anemia7-year follow-up10resolvedgrade 3 (SAE)Autoimmune haemolytic anemia7-year follow-up145resolvedgrade 2Anti-neutrophil cytoplasmic antibody7-year follow-upNAnot resolvedgrade 1Anti-nuclear antibody positive test7-year follow-up1,093resolvedgrade 1Anti-nuclear antibody positive test7-year follow-up1,023resolvedgrade 1Anti-nuclear antibody positive test7-year follow-upNAnot resolvedgrade 1Anti-nuclear antibody positive test7-year follow-upNAnot resolvedgrade 1Anti-smooth muscle antibody positive test7-year follow-up1,373resolvedgrade 1Anti-smooth muscle antibody positive test7-year follow-up877resolvedgrade 1Positive direct Coombs test7-year follow-up1,242resolvedgrade 1Autoimmune thyroiditis≥8-year follow-up743resolvedgrade 1Antinuclear antibody positive test≥8-year follow-upNAnot resolvedgrade 1[^12][^13]

Hepatic Events {#sec2.8}
--------------

Prior to GT, clinically relevant AEs included grade 1 cholelithiasis and liver haemangioma (one patient), grade 1 hepatomegaly and abnormal liver ultrasound (one patient), and grade 1 hepatomegaly (two patients). Following or during busulfan conditioning and GT, 12 patients showed 34 hepatic laboratory abnormalities or hepato-biliary disorders; 16 events were altered liver function tests (liver transaminases or alkaline phosphatase). Grade 1 hepatic steatosis was reported in one patient during 3-month follow-up and in three patients during LTFU. Potential contributing factors to hepatic steatosis included cholelithiasis, dyslipidemia, hepatic fibrosis, busulfan exposure, increased hepatic enzymes, and reactivated Epstein-Barr infection. Most hepatic events were grade 1. Autoimmune hepatitis was the only hepatic SAE reported.

Malignancy {#sec2.9}
----------

As of June 2017, no malignancies have been reported within this patient population (A.A., unpblished data). As of the May 2014 data cut, a benign fibrolipoma (one patient)[@bib24] and skin papillomas (warts) (three patients) were reported post-GT. Grade 1 abnormal protein electrophoresis was reported in three patients; all of these events resolved. One patient reported an AE of increased IG that resolved over 3 years. All patients have a polyclonal T cell Vβ repertoire with more than a single Vβ family represented. Bone marrow morphology evaluations and immunophenotype revealed developing lymphocyte, myeloid, and erythroid cells but no clinically significant alterations. Cytogenetic analyses (karyotypes) were normal in bone marrow and peripheral blood; no abnormal blast values were found in either peripheral blood or bone marrow. All tests for replication competent retrovirus in bone marrow and peripheral blood yielded negative results.

Previously, we reported retrovirus insertion site (RIS) analysis[@bib24], [@bib25] that was complemented by further analysis on 14 patients at a single time point.[@bib19] To validate this data, nine patients were re-tested using whole-blood or peripheral-blood mononuclear cells collected at more recent time points. Bioinformatics analysis of this new sequencing data (comprising 29,777,849 reads) identified a total of 3,225 insertion sites. Comparison revealed that 547 (14.5%) of the RIS previously detected were also recovered during this new analysis. Collision rates between samples were high, and following bioinformatics processing the insertion site diversity ranged between 22 and 441 for the patients tested. Test-retest data showed that both the reproducibility and sensitivity of the assay were low. Due to the limitations of the testing method, the data were not suitable for drawing conclusions on integration abundance, repertoire, and ultimately on the safety profile of GT. A new test system has now been developed and will be the subject of future publications.

Discussion {#sec3}
==========

Here, we provide comprehensive safety evaluation from a GT-treated cohort of patients with ADA-SCID that contributed to the data package for the approval of autologous GT (Strimvelis) for ADA-SCID in the EU in 2016. The listings provided here reveal unique insights into the clinical history of both pre- and post-treatment ADA-SCID. Importantly, AE grade, treatment phase, and duration are available for opportunistic infections; neurologic, CNS, and hearing events; and events related to autoimmunity. This first-of-its-kind dataset comprehensively describes the overall health of these patients, including areas of specific safety interest, in addition to their response to GT. In contrast, previous publications of alternative ADA-SCID treatments have focused on efficacy and death due to specific causes but did not provide detailed analyses of AEs and other safety-related outcomes, as they were not designed to collect events after treatment.[@bib26], [@bib27], [@bib28], [@bib29]

Children with ADA-SCID commonly suffer from a variety of opportunistic infections, including viral, fungal, and mycobacterial infections. Due to defects in B cells and IG production, they are also susceptible to infection with encapsulated bacteria such as *Haemophilus influenzae*, *Streptococcus pneumoniae*, and *Moraxella catarrhalis*.[@bib30], [@bib31] Persistent infections with opportunistic organisms, including *Candida albicans*, VZV, *Aspergillus*, and *Cryptosporidium* are not uncommon and may lead to serious complications or death.[@bib23], [@bib32], [@bib33] Infections of the respiratory tract (upper respiratory tract, rhinitis, bronchitis, nasopharyngitis, pneumonia, and sinusitis) and gastrointestinal tract (gastroenteritis/enteritis along with diarrhea) were the most frequently reported AEs in this study. UTIs were identified as events of special interest because the observed overall incidence (especially in males) was higher than expected.[@bib34] Importantly, all male patients with UTIs also had conditions that predispose for UTI,[@bib35] and the rate of UTIs in the 3-year follow-up period was comparable to those estimated for the general US pediatric population.[@bib36] No males reported UTIs during the 7-year and \>8-year follow-up phases.

During the 3-year and 7-year follow-up phases, the rate of *Candida* infection was higher than that published for the general UK pediatric population,[@bib37] but the rate of *Varicella* infection was comparable to other socialized European children.[@bib38], [@bib39] During the 3-year follow-up period, gastroenteritis occurred at a higher rate than is observed for the general pediatric population,[@bib40] but there were no reports of gastroenteritis during the 7-year and ≥8-year follow-up periods. Infection incidence rates were highest in the pre-treatment to 3-month hospitalization period and decreased with time, a finding expected in subjects undergoing immune reconstitution.[@bib18], [@bib19] Generally, incidence rates dropped over time until they were similar to those reported for the general pediatric population.

AEs in the blood and lymphatic system organ class (including anemia, neutropenia, and thrombocytopenia) were most frequently reported during the 3-month follow-up phase. As expected, the majority of these events occurred within the first 35 days post-GT, indicating that they were likely a consequence of conditioning with busulfan; granulocytopenia, thrombocytopenia, and anemia are all adverse drug reactions reported for busulfan therapy.[@bib41] Hepatic events were identified as special interest due to the known association of busulfan with elevations in transaminases and hepatic veno-occlusive disease (VOD). The incidence of hepatic enzyme increases peaked immediately following busulfan treatment during 3-month follow-up and then declined. These events are consistent with those commonly associated with bone marrow transplantation and are likely reduced in number and severity due to the low-dose regimen applied here. No VOD events were reported.

CNS abnormalities are frequently reported manifestations of ADA-SCID, including in long-term survivors of bone marrow transplantation (BMT).[@bib5], [@bib10], [@bib42], [@bib43], [@bib44], [@bib45] Reported neurological deficits include cognitive impairment (mental retardation, low IQ, reduced verbal skills, and learning disabilities), behavioral abnormalities, sensorineural hearing deficits, motor dysfunction, developmental delays, hypotonia, and abnormal brain MRIs. PEG-ADA treatment prior to SCT does not seem to correct these impairments,[@bib10], [@bib42], [@bib43], [@bib44], [@bib45] despite the previously reported improvement of neurologic manifestations in two patients following reduction of metabolite concentrations.[@bib46] In a cross-sectional study of 105 patients with congenital immunodeficiencies surviving after SCT (56 of whom had SCID or ADA-SCID), it was reported that the underlying genetic disease, presence of ADA-SCID, and consanguinity were each associated with a worse intelligence outcome.[@bib47] Moreover, patients who had a more severe clinical course (i.e., admission to the intensive care unit) had a worse neurocognitive outcome post-SCT. Lower socioeconomic status was also associated with poor outcomes, while the age at transplantation, length of stay in the hospital, and conditioning regimen were not considered significant risk factors. Unsurprisingly, most patients described here reported neurological findings at baseline despite prior receipt of ERT. These manifestations may have been related to the underlying ADA-SCID pathology, sequelae from previous infections (e.g., meningitis, otitis media), and/or prior antibiotic treatment (e.g., gentamycin). Here, we report additional neurologic and hearing AEs post GT; however, we are unable to differentiate between the underlying disease state and GT-related procedures/medications[@bib41], [@bib48], [@bib49], [@bib50] (SCT, busulfan conditioning, and antibiotic prophylaxis/treatment) as potentially contributing factors. There was no indication that baseline neurological AEs improved following GT.

Patients with ADA-SCID may experience autoimmune AEs after SCT (and/or during ERT) that are thought to be related to immune dysregulation prior to achieving complete immune reconstitution.[@bib51], [@bib52] The more common autoimmune manifestations include hemolytic anemia, hypothyroidism, and immune thrombocytopenia.[@bib1], [@bib53], [@bib54] Following treatment with GT, HSCT, and/or PEG-ADA, early-onset ADA-SCID patients may have a response (atopy) to common allergens such as food or inhalants.[@bib55] Reports of autoimmunity and allergy-related events have also been described in delayed-onset ADA-SCID.[@bib1], [@bib56], [@bib57] Several autoimmune events occurred pre-treatment. The majority of post-GT events occurred within 3-year follow-up, mainly consisted of positive autoantibody tests without associated clinical manifestations, and were consistent with ongoing immune reconstitution. Peripheral blood CD19^+^ B cells and CD3^+^ T cells, red blood cell deoxyadenosine nucleotide (dAXP) levels, and anti-CD3 monoclonal antibody (mAb) proliferative responses were similar between patients with and without autoimmune events (data not shown). Autoimmune events are commonly associated with HSCT, PEG-ADA treatment, and the underlying disease state.[@bib58] Importantly, there were no indications that any autoimmune events were specifically attributable to the GT medicinal product.

GT with integrating vectors introduces a risk of insertional mutagenesis through activation of proto-oncogenes, the formation of *de novo* gene expression products, and knockout of tumor suppressor gene function.[@bib59] As a result, leukemic transformation is a leading safety concern for GT. Hematologic malignancies and abnormalities following RV GT have been observed in patients treated for X-linked SCID,[@bib60] chronic granulomatous disease,[@bib61], [@bib62], [@bib63] and Wiskott-Aldrich Syndrome.[@bib64] Importantly, no cases of leukemia have been reported in the cohort described here, despite more than a decade of follow-up in several patients. Moreover, none of the other 22 patients with ADA-SCID who underwent alternative GT regimens over the past decade have developed leukemia.[@bib21], [@bib65] Additional RIS analysis confirmed the existence of several thousand unique insertion sites. As is expected for a pseudo-randomly inserting vector, RIS were detected in areas of known risk.[@bib55] However, clones with these inserts are stable and are not causing clinical safety issues for patients. Insertion site diversity (the number of recovered sites) was comparable to similar gamma retroviral GT trials.[@bib66]

All 18 patients who have been treated with RV GT for ADA-SCID are alive, clinically well, and without signs of leukemic transformation. The safety data presented here provide a first-of-its-kind assessment describing detailed short-term and medium-term follow-up, including infections, hepatic events, autoimmune manifestations, and neurologic/hearing impairments. Monitoring of this cohort is ongoing and will be incorporated into a registry for these and future patients, planned in agreement with pharmacovigilance guidelines for GT products. Such a registry is vital to establish the long-term safety of GT for the treatment of patients with ADA-SCID and to allow accurate comparisons of this new treatment with SCT, ERT, and the emerging class of lentiviral-based GT vectors.[@bib67] Long-term safety and efficacy data from the registry will be made publicly available as the cohort matures.

The safety data reported here are consistent with those available for the general ADA-SCID population[@bib29] and indicate that GT can safely restore immune function in these patients. Immune reconstitution leads to a decrease in the rate of infections following GT, in many cases to rates similar to those within the general pediatric population. The patients discussed here, for whom other treatment options were limited, safely underwent GT and in most cases corrected the metabolic defect and achieved immune reconstitution.

Materials and Methods {#sec4}
=====================

Study Design {#sec4.1}
------------

Two pilot studies,[@bib17], [@bib18], [@bib19] one pivotal study with a LTFU component,[@bib18], [@bib19] and a compassionate use program[@bib19] (CUP; established in accordance with the Italian Ministerial Decree of 8 May 2003) enrolled patients with ADA-SCID. LTFU is ongoing and permitted enrollment of patients from the pilot studies and CUP to participate in long-term assessments beyond the initial follow-up period. All studies were non-randomized, single-arm, and open label. The pivotal study and LTFU are registered at <https://www.clinicaltrials.gov> as \#NCT00598481.

One patient was enrolled and treated at Hadassah Hebrew University Hospital in Jerusalem (Israel). The second pilot study, pivotal study, LTFU, and CUP were administered at San Raffaele Scientific Institute in Milan (Italy) and approved by the Institutional Ethics Committee and the Italian National Regulatory Authorities. All studies complied with Declaration of Helsinki protocols.

Ad hoc data regarding survival and malignancies were provided in June 2017 (A.A., unpublished data); it is not from a validated database or a pre-specified analysis. Data cut for all other results was May 2014 (to match the data provided in the regulatory filings).

Patients {#sec4.2}
--------

All patients' parents provided written informed consent. All patients were under 18 years of age, diagnosed with ADA-SCID, and lacked an HLA-identical sibling donor. All patients had either previously received ≥6 months of PEG-ADA treatment with demonstrated suboptimal efficacy/intolerance, or PEG-ADA was not a long-term treatment option for them.

Pre-treatment {#sec4.3}
-------------

A CVC was placed during the pre-treatment phase. Back-up HSCs were harvested and cryopreserved in case of poor engraftment or technical issues with product manufacture. Patients receiving ERT ceased PEG-ADA administration 10 to 22 days before treatment. The chemotherapy agent busulfan was given as non-myeloablative conditioning to prepare the bone marrow compartment for HSC engraftment. Administration was divided into eight doses of 0.5 mg/kg, administered over study days −3 and −2. Equivalent oral doses (four doses of 0.6 mg/kg) were administered to one patient when i.v. dosing was not feasible. Busulfan dose was reduced if plasma levels exceeded 4000 ng/mL\*h, as measured after the first and fifth doses. This regimen is approximately 20%--25% of the typical dosage used in a myeloablative conditioning regimen[@bib41], [@bib68] and was selected with the intent to promote enhanced gene-modified HSC engraftment while minimizing toxicities associated with intensive chemotherapy.[@bib18]

GT {#sec4.4}
--

Mononuclear cells were harvested from bone marrow under general anesthesia. An RV was used to transduce purified CD34^+^ cells with the human ADA cDNA sequence.[@bib17], [@bib18] On the day of GT, patients were intravenously infused with the transduced autologous CD34^+^-enriched cell fraction (Strimvelis, GSK2696273).

Concomitant therapy usually included pentamidine as first-line *Pneumocystis jirovecii* prophylaxis from before GT until recovery of white blood cell (WBC) count, then switched to cotrimoxazole.[@bib69] i.v./oral antibacterial and antifungal prophylaxis was administered according to SCT guidelines.[@bib70] Acyclovir was used as a herpes simplex prophylaxis and was typically administered until complete immunological reconstitution was achieved. Pre-emptive therapy with ganciclovir or foscarnet was administered according to SCT guidelines for patients who were *Cytomegalovirus* positive by PCR. Pre-emptive therapy with rituximab was used in patients who were Epstein-Barr virus positive by PCR and experienced a substantial increase in cellular viral load.

Outcomes {#sec4.5}
--------

The key efficacy endpoint assessed was survival. Efficacy endpoints are reported elsewhere.[@bib19]

Safety assessments included vital signs, physical examination (normal/abnormal), electrocardiogram (normal/abnormal), urinalysis, bone marrow morphology, bone marrow immunophenotype, bone marrow karyotype, peripheral blood karyotype, and replication competent retrovirus testing. Hematologic assessments included red blood cells (RBCs), WBCs, neutrophils, lymphocytes, monocytes, eosinophils, basophils, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelets, reticulocytes, and erythrocyte sedimentation rate (ESR). Clinical chemistry assessments included AST, alanine aminotransferase (ALT), C-reactive protein (CRP), lactate dehydrogenase (LDH), total bilirubin, indirect bilirubin, glucose, blood urea nitrogen (BUN), creatinine, creatinine phosphokinase (CPK), sodium, potassium, calcium, chlorine, magnesium, phosphorus, alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), total protein, albumin, iron, transferrin, ferritin, FT3, FT4, thyroid-stimulating hormone (TSH), XDP, prothrombin time (PT), activated partial prothrombin time (aPTT), and fibrinogen. Specialist examinations included ophthalmology, neurology, psychology, cardiology, and ear/nose/throat. Instrumental tests included electrocardiograms, chest X-ray, abdominal ultrasound scan, chest CT, echocardiogram, brain/sinus MRI, brainstem auditory evoked potential, visual evoked potential, tympanometry/audiometry, electroencephalography, hand bone X-ray, and respiratory function tests (for patients \>5 years of age). Assessments were performed at baseline and then at intervals during the first 8 years post-GT. Subsequently, patients continue to be evaluated clinically at either their local hospital or San Raffaele Hospital.

AEs {#sec4.6}
---

AE reporting was started from the date of GT onward. Per protocol, pre-treatment events were recorded as concomitant diseases. These events were then retrospectively reported as AEs to provide a baseline, conform to GSK standards, and accommodate regulatory requirements. All AEs were assigned to 1 of 6 phases: pre-treatment (start date after screening visit but prior to day −4); treatment (start date on day −4 up to and including start of GT \[day 0\], includes the timing for busulfan conditioning); 3-month follow-up window (day 1, after infusion of investigational medicinal product, up to and including day 136); 3-year follow-up window (day 137 to day 1,278); 7-year follow-up window (day 1,279 to day 2,739), and ≥8-year follow-up window (≥day 2,740). However, except for those events that required hospitalization or for which severity was specified in the available clinical records, pre-treatment events that may have been serious cannot be specifically determined. The numbers of pre-treatment SAEs are, therefore, likely underestimated. The events reported during the pre-treatment phase may have been ongoing at the time of study enrollment and may reflect concomitant disease history. During the treatment phase, only unexpected or severe conditions were reported as AEs. In any given phase, only those AEs that were new or worsened after the start of a particular phase were reported. Any AE with an unknown outcome,or with a missing resolution date on the clinical report form was recorded as unresolved in the database. A manual review was conducted to identify any conditions ongoing at screening and potentially related to central CNS, autoimmunity, hepatic disorders, and opportunistic infections. AE toxicity was classified using standard Common Terminology Criteria for Adverse Events (CTCAE) (version 4) criteria.[@bib71]

Based on the expected events in patients with ADA-SCID, the risks of GT, regulatory guidance, and the reporting of treatment-related AEs, the following events were identified as AEs of special interest: infections; neurologic and hearing AEs; immune reactions (including AEs possibly related to autoimmunity); oncogenesis events; and hepatic laboratory abnormalities and events. These denote events that the study sponsors and/or regulatory officials felt necessitated specific tracking due to their anticipated frequency or potential impact. Where available, Standardized MedDRA queries have been used to facilitate identification of cases of interest from the AE database that contain terms related to signs, symptoms, diagnoses, syndromes, physical findings, or laboratory test data that may be associated with a medical condition of interest. Custom searches were developed in some instances where a standardized query was not available or was inadequate.

A manual search of available AE listings (by preferred term and verbatim term) and of listings for prior medical conditions was performed. SAE narratives and AEs known to be associated with autoimmunity were reviewed to identify additional events. Laboratory testing for autoimmune antibodies (anti-nuclear antibody, anti-neutrophil cytoplasmic antibody, anti-smooth muscle antibody, direct Coombs test, liver kidney microsomal antibody, and mitochondrial antibody) was conducted during LTFU but was not checked at each visit for every patient. Antibody positivity detection was recorded as an AE by the investigator, even when not associated with clinically relevant events.

Safety Analysis {#sec4.7}
---------------

Not all patients had data available for all time periods. All patients, with the exception of one patient, had data available from pre-treatment through 3-year follow-up. Two patients withdrew from follow-up after receiving successful matched-sibling SCTs. All other patients are enrolled in LTFU and are contacted each year by the clinic center but have varying durations of follow-up. Safety data were summarized only; statistical analysis was not performed.

RIS Analysis {#sec4.8}
------------

Each patient sample was run in triplicate (three biological replicates), and each biological replicate was digested with three restriction enzymes. After bioinformatic analysis, the data for the three enzymes were combined to create one dataset for each biological replicate. The variability of the assay in terms of RIS recovery concordance and the standard deviation of the abundance estimates between the three biological replicates from each patient were analyzed.
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[^1]: These authors contributed equally to this work.

[^2]: AE, adverse event; CT, computed tomography; GT, gene therapy; IgE, immunoglobulin E, LTFU, long-term follow-up; SAE, serious adverse event. In any given phase, only those AEs that were new or worsened after the start of a particular phase were reported.

[^3]: Pre-treatment AEs include any AEs with a start date from the screening visit but prior to day −4 from the date of GT. Pre-treatment events were originally recorded as concomitant diseases and were retrospectively reclassified as pre-treatment AEs. The events reported during the pre-treatment phase may have been ongoing at the time of study enrollment and may reflect concomitant disease history. However, events that may have been serious but did not meet criteria cannot be determined. The numbers of pre-treatment SAEs are therefore likely underestimated.

[^4]: One patient started follow-up at year 13 but had AEs reported at year 8 and year 12, which are included.

[^5]: An AE of pharyngitis occurred in the LTFU, but the dates were not known so it appears in the Total column only.

[^6]: The neoplasms system organ class includes benign, malignant, and unspecified, including cysts and polyps.

[^7]: Adapted from Cicalese et al.[@bib19]

[^8]: Identified as an event potentially related to autoimmunity (verbatim term: prolonged neutropenia \[anti-neutrophils antibodies positive\]).

[^9]: AE, adverse event; NR, not reported; SAE, serious adverse event. CMV and EBV reactivation occurred each in one patient early after treatment; primary *Varicella* infection occurred in four patients without complications, followed by specific antibody responses. In any given phase, only those AEs that were new or worsened after the start of a particular phase were reported.

[^10]: AE, adverse event; BAER, brainstem auditory evoked response; EEG, electroencephalogram; NR, not recorded; VEP, visual evoked potential. In any given phase, only those AEs that were new or worsened after the start of a particular phase were reported.

[^11]: Relevant medical conditions ongoing at screening, which are not reported as AEs, were identified via manual review and are included in this table for completeness.

[^12]: AE, adverse event; NA, not applicable; NR, not reported; SAE, serious adverse event. In any given phase, only those AEs that were new or worsened after the start of a particular phase were reported.

[^13]: Event was identified in SAE narrative as possibly related to autoimmunity.
